Laurent Pharmaceuticals Provides Clinical Development Update

MONTREAL, QC, Canada – April 8th, 2021

  • Announces Positive Outcome of Pre-Planned Interim DSMB Safety Review and Futility Analysis for Phase 2 RESOLUTION Study in Hospitalized COVID-19 Patients
  • Completes Enrollment in Phase 2 APPLAUD Study in Patients with Cystic Fibrosis
  • Topline Results Expected in H2 2021 for both RESOLUTION and APPLAUD Studies

Read more ...

Laurent Pharmaceuticals Joins Battle Against COVID-19

MONTREAL, QC, Canada – April 9th, 2020

Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company that spun off from McGill University in 2012, today announces that it is planning to test its lead drug LAU-7b in patients with COVID-19 disease, as part of a Phase 2 clinical trial.

Read more ...


Laurent Pharmaceuticals to participate at BIO Digital 2021, June 10-11 & 14-18, 2021